> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Orphan Drugs Info Collection Revision
- URL: https://www.fdaweb.com/orphan-drugs-info-collection-revision/
- Published: 2020-10-02T12:00:00.000Z
- Updated: 2026-09-14T16:31:16.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147790

*Federal Register* notice: FDA is seeking comments on an information collection revision for “Orphan Drugs; 21 CFR Part 316” (OMB Control Number 0910-0167). The collection is being revised to include *Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff on Meetings With the Office of Orphan Products Development*, which provides recommendations to industry, researchers, patient groups, and other stakeholders interested in requesting an FDA meeting, including a teleconference, about issues related to orphan drug designation requests, humanitarian use device designation requests, rare pediatric disease designation requests, funding opportunities through the Orphan Products Grants Program and the Pediatric Device Consortia Grants Program, and orphan product patient-related topics. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-10-02/pdf/2020-21843.pdf?ref=fdaweb.com).